Saturday, May 22, 2021 11:53:03 AM
An update for you !! I compiled an email using your excellent points regarding possibly "unrecognized" assets in Northwest's asset pool and presented the following to a person(s) in a very influential position!!!
My email:
Hey There,
Some thoughts on creating value for Northwest. My view is that Northwest has an extremely valuable tumor tissue library and patient DNA library for virtually any cancer in the world for enhancing understanding and treatment!!! AND it is totally unique to Northwest.
This is the most valuable aspect of the treatment yet to be discussed or maybe even understood as it relates to the discussion of commercialization. Of course it’s derived from the treatment, but it should be recognized as an incredible resource that’s never been available to the world of cancer research in the pursuit of a broad cure for cancer!!!
I think LP is very traditional and this might be something that she’s not interested in pursuing , but they are focused on commercializing and securing approval for DCVax-L and this could be an important facet to the yet uncut “diamond” !!!
I’m convinced that this idea clearly reflects the enormous potential of Northwest from a partnership perspective/strategy, if they could fully articulate and develop a deep platform strategy.
Think about the potential for a “Google” or “Microsoft” as a fit for their AI, Big Data projects!!! This is definitely something that brilliant minds other than mine(??) are thinking about!!! I can’t emphasize enough how valuable this asset is to Northwest and I don’t want it to be “lost in the shuffle!!!”. If you agree, maybe you can get this in front of Powers and Goldman.
Cheers,
I received an almost immediate response!!!
Brian, You are correct, lots of value . You need not worry about LP and LG missing the value of data.. I have been emphasizing to them and potential share buyers since late 2019 that the marathon of all cancer trials has accumulated more data than any and right next door at Cambridge are some of world’s outstanding AI geniuses and together great new things will emerge and that our vast data asset is priceless.
They agree and emphasize that our Sawsten facility will also include labs/offices for such research .
Keep on emphasizing as the data are super valuable !!!
And my reply:
I knew you would be all over it! Just didn’t know how receptive management would be or better said, would have time to be!!?? We both know how difficult it is for a small biotech company to survive and how nearly impossible agency approvals are AND how BP adds to the effort to stall and thwart new innovative treatments.
The parallels between Northwest and many other small biotech industry players are too numerous to count and the only way to change the ending of this movie for Northwest is for people like you and me to fight like hell to help LP and LG rewrite the script, which is what we’re doing!!!????
And my comment to you, Bio and all the other wonderful contributors on this board and elsewhere that are fighting to bring this wonderful treatment to the "light of day"!!!
"Keep fighting!!! Never quit!! Never give up and never give in to the naysayers whose only motivation is the frustrations from either their own life's failures or the regrets they have for never trying to accomplish the seemingly impossible when the opportunities were before them!!!!
Cheers,
BB
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM